Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXHALE-4 dexpramipexole in eosinophilic asthma
MOH_2023-11-09_013039Phase 3Not yet recruiting
- Sponsor
- Areteia Therapeutics
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexpramipexole in eosinophilic asthma (EA) (3 arms), sponsored by Areteia Therapeutics. Primary endpoint: Primary efficacy endpoint. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
dexpramipexole
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on MOH_2023-11-09_013039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-11-09_013039.